AICAR Explained: What It Is and What the Name Actually Refers To
For laboratory research use only. Not for human or veterinary use.
AICAR is the most commonly mislabelled compound in the research catalogue, and the mislabelling is not carelessness — it is baked into the name. “AICAR” is used in the published literature for two different molecules that differ by a phosphate group, eighty atomic mass units, and whether they can cross a cell membrane at all. This guide sets out which is which, why it matters when you read a certificate, and what the compound does.
Two molecules, one abbreviation#
| What is sold as AICAR | What AICAR means in biochemistry | |
|---|---|---|
| Proper name | Acadesine | AICA ribonucleotide |
| Also called | AICA riboside, AICAR | ZMP, AICA ribotide, AICAR |
| Class | Nucleoside | Nucleotide (phosphorylated) |
| Molecular formula | C9H14N4O5 | C9H15N4O8P |
| Molar mass | 258.23 g/mol | 338.21 g/mol |
| CAS number | 2627-69-2 | — |
The difference is one phosphate group, and it is the difference between a compound that enters cells and one that does not. Phosphate groups carry charge; charged molecules do not cross lipid membranes unaided. The nucleotide form cannot get in. The nucleoside form can.
What every supplier sells as AICAR is acadesine, the nucleoside — molar mass 258.23, CAS 2627-69-2. If you see 338 on a certificate, that is not what was ordered.
How it works#
The mechanism is unusually elegant, and understanding it explains why the naming confusion exists in the first place.
Acadesine is an analogue of adenosine, close enough in shape that it enters cells through the same nucleoside transporters. Once inside, adenosine kinase phosphorylates it — converting it to the nucleotide form, ZMP. The compound that could not get in is therefore manufactured on the inside, from the one that could.
ZMP structurally resembles AMP, adenosine monophosphate. AMP is the cell's low-fuel signal: when ATP is consumed, AMP accumulates, and rising AMP allosterically activates AMP-activated protein kinase (AMPK), the enzyme that switches cellular metabolism from storage to consumption.
ZMP occupies the same regulatory site. AMPK responds as though AMP had risen — but no ATP has been spent and the real nucleotide ratios are unchanged. The compound does not deplete cellular energy; it mimics the signal that energy has been depleted.
That is what makes it a research tool rather than a curiosity. It lets AMPK activation be studied as a variable in its own right, separated from the energy stress that would normally cause it.
It is also a natural metabolite#
Worth stating plainly, because it is often missed: AICA ribonucleotide is not a foreign molecule. It is a genuine intermediate in de novo purine biosynthesis — the pathway by which cells build purine bases from scratch — sitting on the route to inosine monophosphate.
So the compound is not introducing a novel chemical entity to the cell. It is raising the concentration of something the cell already makes, at a point where that molecule happens to resemble a regulatory signal.
Where it came from#
Acadesine was developed in the 1980s, investigated for cardiac protection during surgery rather than for anything metabolic. The proposed mechanism involved nitric oxide and ATP-sensitive potassium channels.
It was licensed to Schering-Plough in 2007 and entered the RED-CABG Phase III trial in May 2009. The trial was terminated in late 2010 following an interim futility analysis, which concluded it had a low probability of meeting its primary efficacy endpoint. It has never been approved for clinical use anywhere.
The reason anyone outside cardiology has heard of it is separate. In 2008, research in mice reported metabolic effects that drew attention well beyond the laboratory.
Anti-doping status — read this before ordering#
Following that 2008 research, the World Anti-Doping Agency added acadesine to its Prohibited List from 2009, under Class S4, metabolic modulators. It was subsequently reported as detected in cycling.
The practical consequence: anyone subject to anti-doping testing should not handle this compound, and any laboratory whose work involves tested populations should regard its presence as a controlled matter. This is a straightforward fact about the compound and it belongs on a supplier's page rather than being left for the customer to discover afterwards.
What to check on the certificate#
- Mass spectrometry: 258.23, not 338.21. This is the single most important check and it is specific to this compound. The 80 g/mol separation between nucleoside and nucleotide is unmistakable on a mass spectrum. A certificate reporting the higher mass has not characterised the material that was ordered.
- HPLC purity, with the method named. Reported as measured on that batch. A figure without a method behind it is a number, not a result.
- Water content. Acadesine is hygroscopic. Mass measured on a damp sample is not mass of compound, and a batch stored badly before testing will read light on assay.
- Appearance. White to off-white crystalline powder. Discolouration is a reason to ask questions before use.
Ask about the documentation for the batch we would ship before you order. The guides on reading a COA and what a purity figure means go through each of these.
Handling — it is not a peptide#
Most of what we supply is peptide, and peptide handling rules do not transfer here. Acadesine is a small-molecule nucleoside: a single ribose-linked heterocycle, not a chain of amino acids. It has no secondary structure to lose, which means it is not denatured by agitation and does not carry the shear sensitivity that makes peptide handling fussy.
What it is sensitive to is moisture. Keep it sealed, dry and cold, and let a cold vial reach room temperature before opening — condensation on cold powder is the realistic failure mode for a hygroscopic compound. It is water-soluble, which simplifies preparation relative to compounds requiring an organic co-solvent.
The storage guide covers general conditions, and the equipment guide covers transfer.
What Pioneer supplies#
AICAR is stocked as acadesine. A batch certificate is not currently published for this compound; contact us for the documentation available on the batch in stock. It ships from the UK with same-day dispatch on orders before 2pm.
Quality comes first#
With a compound whose own name refers to two different molecules, documentation is not a formality — it is the only way to know which one is in the vial. Ask us what documentation exists for the batch in stock before ordering rather than after.
Sources#
Each entry links to its PubMed record, where the title and abstract can be read. The descriptions are ours: they say what each paper examined, not what it is claimed to show. Records checked on PubMed on 28 October 2026.
- Corton JM, Gillespie JG, Hawley SA, et al. (1995). Eur J Biochem 229(2):558–65. The Dundee study showing that cells convert AICAR to ZMP, which activates AMPK without changing the cell’s ATP, ADP or AMP. PubMed 7744080
- Narkar VA, Downes M, Yu RT, et al. (2008). Cell 134(3):405–15. The Salk Institute mouse study of AMPK and PPARδ agonists and treadmill endurance that drew attention to AICAR outside the laboratory. PubMed 18674809
- Pokrywka A, Cholbinski P, Kaliszewski P, et al. (2014). J Physiol Pharmacol 65(4):469–76. Anti-doping review: why AICAR was added to the WADA Prohibited List in 2009, and how laboratories detect it. PubMed 25179079
- Mangano DT (1997). JAMA 277(4):325–32. Meta-analysis of the five earlier randomised trials in heart-bypass surgery (4,043 patients). It met its primary outcome, and its result led to the RED-CABG trial. PubMed 9002496
- Newman MF, Ferguson TB, White JA, et al. (2012). JAMA 308(2):157–64. RED-CABG, the phase 3 trial in heart-bypass surgery. Stopped after 3,080 of a planned 7,500 patients when a futility analysis showed no difference in the primary outcome. PubMed 22782417
- Višnjić D, Lalić H, Dembitz V, et al. (2021). Cells 10(5):1095. Systematic review of the AICAR effects that turn out not to depend on AMPK, with a caution on how AICAR-based studies are read. PubMed 34064363
In our catalogue#
- AICAR — AMPK activation research, 50mg and 100mg
- 5-Amino-1MQ — NNMT inhibition, metabolic research
- MOTS-c — mitochondrial-derived peptide, metabolic signalling
Pioneer Research Peptides — UK supplier of research peptides for laboratory use. Ask about batch documentation before you order.
For laboratory research use only — not for human consumption. 18+.
Research compounds from UK stock#
Supplied for laboratory research use only. Ask about the documentation for a batch before you order.
